Loading
companiesCompany
Lepu Biopharma
Lepu Biopharma is a China-based biotechnology company running 8 late-stage cancer trials of MRG003, Pucotenlimab and MRG006A in head and neck squamous cell carcinoma, nasopharyngeal carcinoma and hepatocellular carcinoma.
Also called: Lepu Biopharma Co., Ltd.
Overview
Lepu Biopharma, based in Shanghai, China, is a biotechnology company. Lepu Biopharma is a China-based, globally focused biopharmaceutical company developing antibody-drug conjugates, oncolytic viruses and other immunotherapies for oncology. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing MRG003, Pucotenlimab, MRG006A and Cretostimogene Grenadenorepvec in head and neck squamous cell carcinoma, nasopharyngeal carcinoma, hepatocellular carcinoma and bladder & urothelial cancer. The largest, NCT06976190 (A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma), plans to enrol 446 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#165of 1244 companies, score 35
- approved products +6
- phase 3 +3
- targets +2
- modalities +4
- regions +1
- registry trials +19
1 approved, 1 in phase 3, 0 earlier, 1 targets, 92 registry studies. Formula on the scorecards page.
Type
Website
Phase 3ADC
MRG003 is an experimental antibody-drug conjugate from Lepu Biopharma in phase 3 trials for head and neck squamous cell carcinoma and nasopharyngeal carcinoma, with its target not yet stated publicly.
ApprovedAnti-PD-1 monoclonal antibody, intravenous
Pucotenlimab is Lepu Biopharma's PD-1 antibody, approved in China in 2022 for mismatch-repair-deficient solid tumours and for melanoma, and in a phase 3 trial in colorectal cancer.
Similar pages
- CancerRecurrent and metastatic nasopharyngeal carcinoma
Shares A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma, A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin, MRG003, Nasopharyngeal carcinoma.
- TargetCYLD
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, Head and neck squamous cell carcinoma.
- TargetCASP8
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, Head and neck squamous cell carcinoma.
- TargetFAT1
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, Head and neck squamous cell carcinoma.
- TreatmentCretostimogene grenadenorepvec
Shares Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin, Bladder & urothelial cancer.
- JournalTumour virus research
Shares Nasopharyngeal carcinoma, Hepatocellular carcinoma, Head and neck squamous cell carcinoma.
- TargetARID2
Shares Nasopharyngeal carcinoma, Hepatocellular carcinoma, Head and neck squamous cell carcinoma.
- PersonAnthony T. C. Chan
Shares Nasopharyngeal carcinoma, Head and neck squamous cell carcinoma.
cancers
drugs
Phase 3ADC
ApprovedAnti-PD-1 monoclonal antibody, intravenous
trials
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic CancerA Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinA Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsA Study of MRG006A in the Treatment of Patients With Advanced Solid TumorsA Study of MRG007 Combination Therapy for Advanced Colorectal CancerA Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell CarcinomaStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin